Structure-based virtual high-throughput screening and molecular dynamics simulations for repurposing FDA-approved drugs as STAT3 inhibitors
Current Pharmaceutical Analysis · 2026-11
DOI: 10.1016/j.cpan.2026.11.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Pharmaceutical Analysis, 2026-11. Verfasst von Guangshuai Zhang und 10 weiteren Autor:innen. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Hunan Provincial Science and Technology Department, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
Background
Signal transducer and activator of transcription 3 (STAT3) is a key oncogenic transcription factor with aberrant activation in diverse malignancies, and its conserved SH2 domain is vital for STAT3 dimerization. In this study, we developed an integrated computational and experimental framework to identify FDA-approved drugs with the potential to target the STAT3 SH2 domain and investigate the molecular mechanisms underlying ligand recognition.
Methods
A total of 1,600 FDA-approved compounds retrieved from the ZINC database were subjected to structure-based virtual high-throughput screening (vHTS) against the STAT3 SH2 domain. Top-ranked hits were further evaluated through molecular docking, 100-ns molecular dynamics (MD) simulations and MM/GBSA binding free energy calculations. A representative compound was subsequently assessed using surface plasmon resonance (SPR) and CCK-8 cell viability assays.
Results
Five compounds, digoxin, irinotecan, dutasteride, ledipasvir, and eribulin, exhibited favorable predicted binding to STAT3. MD simulations indicated that all five ligand–STAT3 complexes remained conformationally stable, with Tyr640 and Tyr657 emerging as conserved interaction hotspots contributing to complex stability. Comparative analysis suggested that digoxin preferentially binds STAT3 over other STAT family members. SPR analysis confirmed direct binding between digoxin and STAT3 (K D = 1.34 × 10 -5 M). CCK-8 assays showed that digoxin significantly reduced HepG2 cell viability in a concentration- and time-dependent manner, with IC 50 values of 2.82 μM and 1.98 μM after 48 and 72 h of treatment, respectively.
Conclusion
This study identified five FDA-approved drugs as potential STAT3 inhibitors, with digoxin emerging as a promising candidate for STAT3-targeted anticancer therapy. Further in vivo investigations and mechanistic studies are warranted to establish their therapeutic efficacy and clinical potential.
Förderung
- National Natural Science Foundation of China
- China Hunan Provincial Science and Technology Department
- Hunan Provincial Natural Science Foundation
- Hunan University of Chinese Medicine
Zitieren
APA
Zhang, G., Liao, Y., Tan, Z., Xie, Q., Liu, Z., Xiao, J., Yan, S., Guo, X., Peng, R., Luo, W., & Qin, S. (2026). Structure-based virtual high-throughput screening and molecular dynamics simulations for repurposing FDA-approved drugs as STAT3 inhibitors. Current Pharmaceutical Analysis. https://doi.org/10.1016/j.cpan.2026.11.003
Vancouver
Zhang G, Liao Y, Tan Z, Xie Q, Liu Z, Xiao J, et al. Structure-based virtual high-throughput screening and molecular dynamics simulations for repurposing FDA-approved drugs as STAT3 inhibitors. Current Pharmaceutical Analysis. 2026. doi:10.1016/j.cpan.2026.11.003
BibTeX
@article{Zhang2026,
author = {Zhang, Guangshuai and Liao, Yingyan and Tan, Ziyu and Xie, Qingqing and Liu, Zishu and Xiao, Jin and Yan, Si and Guo, Xiaoqian and Peng, Rui and Luo, Wei and Qin, Shuanglin},
title = {Structure-based virtual high-throughput screening and molecular dynamics simulations for repurposing FDA-approved drugs as STAT3 inhibitors},
journal = {Current Pharmaceutical Analysis},
year = {2026},
doi = {10.1016/j.cpan.2026.11.003}
}
EUVIMED